Silence Therapeutics plc
SLN
$13.55
-$0.14-1.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 1,141.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 1,141.18% | |||
| Cost of Revenue | -- | -8.33% | |||
| Gross Profit | -- | 1,768.18% | |||
| SG&A Expenses | -32.86% | 88.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.39% | 22.13% | |||
| Operating Income | 13.02% | -19.12% | |||
| Income Before Tax | 17.98% | -27.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.98% | -27.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.98% | -27.08% | |||
| EBIT | 13.02% | -19.12% | |||
| EBITDA | 13.13% | -19.35% | |||
| EPS Basic | 18.00% | -27.09% | |||
| Normalized Basic EPS | 17.99% | -27.10% | |||
| EPS Diluted | 18.00% | -27.09% | |||
| Normalized Diluted EPS | 17.99% | -27.10% | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||